ストックスクリーナーアプリを入手
1.985
1.28%
0.025
前日終値:
$1.96
開ける：
$1.96
24時間の取引高:
182.15K
Relative Volume:
0.25
時価総額：
$231.89M
収益：
-
当期純損益:
$-26.33M
株価収益率:
-7.029
EPS:
-0.2824
ネットキャッシュフロー:
$-17.65M
1週間 パフォーマンス:
+16.08%
1か月 パフォーマンス:
+60.73%
6か月 パフォーマンス:
+98.50%
1年 パフォーマンス:
+71.12%
1日の値動き範囲:
$1.95
$1.99
1週間の範囲:
$1.65
$1.99
52週間の値動き範囲:
$0.88
$1.99
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.985 | 228.97M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 58.57B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.21 | 43.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.865 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.98 | 31.69B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
521.84 | 22.70B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
Cardiol Therapeutics Stock Surges 4.82% as Phase III Progress and CardiolRx Pipeline Support Investor Optimism - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock went up yesterday - Wealth Awesome
Cardiol (CRDL) Financial Results: EPS Exceeds Its Estimate in the Latest Reading; Market Move: The Stock Gains 5.28% on the DayEarnings Manipulation Risk - Vinanet
Cardiol Therapeutics Stock: A Pivotal Pericarditis Readout Draws Nearer - kalkine.ca
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
CRDL Maintains Buy Rating by Canaccord Genuity -- Price Target R - GuruFocus
Why Cardiol Therapeutics Inc Class A stock is gaining today - Wealth Awesome
Cardiol Therapeutics (CRDL) Advances 5.26% as Shares Test Key Resistance Near $1.89IPO Entry Watch - Vinanet
Canaccord Genuity Group Issues Positive Forecast for Cardiol Therapeutics (NASDAQ:CRDL) Stock Price - MarketBeat
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Could Cardiol Therapeutics Stock Be Entering a Major Catalyst Phase as MAVERIC Enrollment Nears Completion? - kalkine.ca
Q3 EPS Estimate for Cardiol Therapeutics Raised by Analyst - MarketBeat
Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome
Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks
Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
What’s Next For Cardiol Therapeutics (TSX:CRDL) Research? - Kalkine Media
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - MarketBeat
Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome
Cardiol Therapeutics at Canaccord Genuity: Phase III catalyst nears By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSX:CRDL): The Oral Heart Drug Challenging Injectable Biologics Nears Its Big Test - kalkine.ca
Cardiol Therapeutics (CRDL) Gains 1.76% to $1.45, Holding Above Key SupportBPI Bull Correction - Vinanet
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday - MarketBeat
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics to Present Heart Disease Pipeline at Canaccord Genuity Growth Conference - TipRanks
Cardiol Therapeutics Inc. (NASDAQ: CRDL) at Canaccord 46th Growth Conference - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference - The Globe and Mail
Cardiol Therapeutics to Join Boston Chat on Heart Disease Therapies - Stock Titan
Cardiol Therapeutics (CRDL) Holds Steady at $1.30 as Shares Consolidate Between Support and ResistanceRegression Channel - dars.gov.et
Cardiol's Pivotal Phase III Heart Trial Reaches 75% Enrolment as Leading U.S. Medical Centres Join the Race - kalkine.ca
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
CRDL|Cardiol Therapeutics Inc|Price:1.300|Chg%:+0.030 - TradingKey
Cardiol Therapeutics Inc. (TSX:CRDL) Shares Decline as Biotech Risk, Clinical Uncertainty and Investor Caution Pressure Outlook - kalkine.ca
HC Wainwright Analysts Decrease Earnings Estimates for CRDL - MarketBeat
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.180|Chg%:-0.050 - TradingKey
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.330|Chg%:+0.020 - TradingKey
Cardiol Therapeutics Inc. Class A Revenue Breakdown – SWB:CT9 - TradingView
CRDL Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pre-Revenue R&D ProgressSpecial Dividend Alert - Vinanet
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
1.22%
0.04%
大文字化:
|
ボリューム (24 時間):